We delve into the exploratory analysis of the DETERMINATION study data, which suggests a potential meaningful progression-free survival (PFS) benefit for African American (AA) patients receiving RVd-alone treatment. We also examine safety findings, noting a similar safety profile between AA and White patients, despite the high prevalence of Duffy-null alleles in AA patients. However, we observe that neuropathic toxicity may be higher in AA patients. Finally, we discuss how these clinical insights could influence treatment decisions for newly diagnosed multiple myeloma patients

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in the treatment of relapsed or refractory haematological cancers, fundamentally altering the landscape of cancer care. By harnessing the body’s immune system, this therapy effectively targets and destroys cancer cells, demonstrating remarkable efficacy particularly in acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma. At the forefront of advancements discussed during EBMT 2024, Dr. Sridhar Chaganti highlighted pioneering strategies, including the development of allogeneic CAR T-cell therapies. These therapies not only exhibit potential in reducing Graft-versus-Host disease but also show promise in improving cell expansion, marking significant progress in overcoming treatment limitations. Moreover, innovative approaches aim to address associated side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Among these, the introduction of the JAK1 inhibitor, itacitinib, stands out as a promising avenue for mitigating adverse reactions and enhancing patient outcomes in the realm of CAR T-cell therapy

Recent studies have highlighted the promising effects of belumosudil, axatilimab and faecal microbiota transplants in treating Graft-versus-Host Disease (GVHD). These significant advancements were underscored at the EBMT 50th Annual Meeting